3 Result: IBio
Market Buzz: CDI Trial Outcome Fuels Acurx Pharmaceuticals
October 02nd, 2023
Shares of Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) surged by more than 20% in pre-market trading following the company's decision to discontinue its Phase 2b clinical trial of ibezapolstat, its lead antibiotic candidate, designed for the treatment . Read more
Triple Impact: iBio's Collaboration, Oracle's Strong Q4, and EVgo's Charging Network Growth Make Waves
June 12th, 2023
iBio, Inc. (NYSE American: IBIO) has partnered with the National Institute of Allergy and Infectious Diseases (NIAID) to explore the potential of the company's AI-driven epitope steering platform in developing a vaccine for Lassa fever, a severe and . Read more
Lucintel Forecasts Feed Enzyme Market to grow at a CAGR of 9% from 2019 to 2024
December 08th, 2021
Dallas, TX / CRWE PRESS RELEASE / Dec. 9, 2021 - According to the recent study the Feed Enzyme Market is projected to grow at a CAGR of 9% from 2019 to 2024. Growth in this market is primarily driven by increasing animal population, high cost of. Read more
Want To Find Some News?
Recent Post
-
Earnings on Deck: WM, Cadence Design Systems, and Nucor in Focus
July 26th, 2025FAA Initiative Will Pump More Controllers into the Workforce
July 26th, 2025Honeywell, Intel, and Dover Earnings Preview: What to Expect
July 20th, 2025All Eyes on Tesla, ServiceNow, and GE Vernova Ahead of Earnings
July 20th, 2025RTX, Texas Instruments, and Northrop Grumman Earnings in Focus
July 20th, 2025
Member Login